Compare Mesoblast Limited (MESO) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Boston Beer Company Inc — how do they compare? Mesoblast Limited trades at $14.21 (market cap $1.75B), while Boston Beer Company Inc trades at $170.52 (market cap $1.76B). The key difference: Mesoblast Limited and Boston Beer Company Inc are close in size by market cap, and Boston Beer Company Inc is more actively traded (264,496 versus 239,027). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Boston Beer Company Inc for 59 Days on average.
| MESO | SAM | |
|---|---|---|
Market Cap | $1.75B | $1.76B |
Volume | 239,027 | 264,496 |
Sector | Health | Consumer Staples |
52-Week High | $20.96 | $260.05 |
52-Week Low | $13.19 | $161.08 |
Typical Hold Time | 14 Days | 59 Days |
Enterprise Value | $1.83B | $1.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Boston Beer Company (SAM) trades at $171.33, up 1.89% with a bullish technical signal despite mixed earnings performance. The stock shows strong cash flow generation with $270M operating cash flow in 2025, but faces profitability challenges with negative net income margin of -3.64%. Recent developments include new product launches and marketing initiatives targeting younger demographics, while analyst consensus remains cautious with 72% hold ratings.
SAM presents a mixed investment case with attractive valuation metrics (P/E 22.7, P/S 0.94) offset by profitability concerns. Upside potential exists from innovation initiatives and brand investments, but investors face risks from volume declines and competitive pressures. The stock trades near consensus price target of $204.44, suggesting moderate upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
